TITLE

Influence of Enzyme-Inducing Antiepileptic Drugs on Trough Level of Imatinib in Glioblastoma Patients

AUTHOR(S)
Pursche, Stefan; Schleyer, Eberhard; von Bonin, Malte; Ehninger, Gerhard; Said, Samir Mustafa; Prondzinsky, Roland; Illmer, Thomas; Yanfeng Wang; Hosius, Christian; Nikolova, Zariana; Bornhäuser, Martin; Dresemann, Gregor
PUB. DATE
September 2008
SOURCE
Current Clinical Pharmacology;Sep2008, Vol. 3 Issue 3, p198
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Imatinib mesylate is used in combination with hydroxyurea (HU) in ongoing clinical phase II studies in recurrent glioblastoma multiforme (GBM). CYP3A4 enzyme-inducing antiepileptic drugs (EIAEDs) like carbamazepine, phenytoin, and oxcarbazepine -- as well as non-EIAEDs like valproic acid, levetiracetam, and lamotrigine -- are frequently used in patients with GBM. Since CYP3A4 is the major isozyme involved in the metabolism of imatinib, we investigated the influence of EIAEDs on imatinib pharmacokinetics (pk). Methods: GBM patients received 600 mg imatinib p.o./o.d. in combination with 1.0 g HU p.o./o.d..together with either EIAEDs, non-EIAEDs, or no antiepileptic drug (non-AEDs) comedication. Trough plasma levels of imatinib and its active main metabolite N-desmethyl-imatinib (CGP74588) were determined biweekly in these patients, total 543 samples being collected from 224 patients (up to 6 times / patient). All three groups were compared to each other and with historical pharmacokinetic data obtained from patients with chronic myeloid leukemia (CML). Results: Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%). Mean trough levels of imatinib were reduced up to 2.9-fold (477 ng/ml, CV 70%) in patients treated with EIAEDs. Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively. The corresponding mean level for CML patients was 300 ng/ml (CV 50%). Conclusion: Significant decreases of imatinib and CGP74588 trough levels were observed for patients receiving EIAEDs. The EIAED-induced reduction in trough imatinib levels can be avoided by switching to non-EIAEDs comedication or compensated by administering higher imatinib doses. In addition these data demonstrate that there is no significant difference in the pharmacokinetics of imatinib between patients with glioblastoma and CML.
ACCESSION #
60434802

 

Related Articles

  • The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. Nicolson A; Appleton R E; Chadwick D W; Smith D F // Journal of Neurology, Neurosurgery & Psychiatry;Jan2004, Vol. 75 Issue 1, p75 

    OBJECTIVE: To examine a large population with idiopathic generalised epilepsy (IGE), and estimate the overall remission rates for the IGEs and subsyndromes in a clinic based sample. Remission rates on valproate, lamotrigine, topiramate, and combinations of these antiepileptic drugs were...

  • Reinvestigation and Reduction of Polytherapy in Children With Chronic Seizures. Chu-Chin Chen; Pao-Chin Chiu; Mei-Tsen Chen // Journal of Child Neurology;Jan2007, Vol. 22 Issue 1, p15 

    From October 2001 to October 2003, the authors reviewed all patients with chronic seizures taking antiepileptic drugs for more than 2 years with follow-up at the pediatric neurological clinic. They identified 31 patients who were using 3 or more drugs. Twenty-nine patients agreed to undergo a...

  • Another Nail in the Coffin. Vining, Eileen P.G. // Epilepsy Currents;May/Jun2010, Vol. 10 Issue 3, p53 

    Cognitive Function at 3 Years of Age after Fetal Exposure to Antiepileptic Drugs. Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW, NEAD Study Group. N Engl J Med 2009;360(16):1597–1605. ...

  • Trigeminal Neuralgia: Current Concepts in the Medical Management. Denny, Ceena E.; Priya, Jeena K.; Ongole, Ravikiran // World Journal of Dentistry;Apr2010, Vol. 1 Issue 1, p43 

    Trigeminal neuralgia (TN), also known as tic douloureux, is characterized by recurrent attacks of lancinating pain in the trigeminal nerve distribution. Typically, brief attacks are triggered by talking, chewing, teeth brushing, shaving, a light touch, or even a cool breeze. The pain is nearly...

  • Phenytoin associated with bone loss in young women.  // Reactions Weekly;5/3/2008, Issue 1200, p4 

    The article discusses research on the effects of antiepileptic drug monotherapy to the bone health of young U.S. women with epilepsy. It references a study by A. M. Pack and colleagues published in the April 29, 2008 issue of "Neurology." The researchers studied the bone health of women who were...

  • The Quantitative Effect of Serum Albumin, Serum Urea, and Valproic Acid on Unbound Phenytoin Concentrations in Children. Heine, Rob ter; van Maarseveen, Erik M.; van der Westerlaken, Monique M. L.; Braun, Kees P. J.; Koudijs, Suzanne M.; Berg, Maarten J. ten; Malingré, Mirte M. // Journal of Child Neurology;Jun2014, Vol. 29 Issue 6, p803 

    Dosing of phenytoin is difficult in children because of its variable pharmacokinetics and protein binding. Possible covariates for this protein binding have mostly been univariately investigated in small, and often adult, adult populations. We conducted a study to identify and quantify these...

  • Treating refractory epilepsy in adults. Reynolds, Edward // BMJ: British Medical Journal (International Edition);3/11/2006, Vol. 332 Issue 7541, p562 

    This article reports on the treatment of refractory epilepsy in adults. Most adults with refractory epilepsy have partial (focal) seizures with or without secondary generalization. Studies from the 1970s and 1980s have shown that 70-80% of adults with newly diagnosed epilepsy could control their...

  • ANTICONVULSANT DRUGS: CARBAMAZEPINE, ETHOSUXIMIDE, PHENOBARBITAL, PHENYTOIN, PRIMIDONE, VALPROIC ACID  // Davis's Comprehensive Handbook of Laboratory & Diagnostic Tests ;Jan2006, p140 

    Anticonvulsants are used to reduce the frequency and severity of seizures for patients with epilepsy. Carbamazepine is also used for controlling neurogenic pain in trigeminal neuralgia and diabetic neuropathy and for treating for bipolar disease and other neurologic and psychiatric conditions....

  • Carbamazepine/phenytoin.  // Reactions Weekly;10/14/2006, Issue 1123, p7 

    The article presents a case study of a 40-year-old man who developed drug rash with eosinophilia and systemic symptoms syndrome during carbamazepine therapy, followed by drug hypersensitivity to previously well tolerated phenytoin. The patient had been taking phenytoin and valproic acid for 4...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics